Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib versus Ibrutinib Maintenance Therapy in CLL/SLL and MCL
ChiCTR2100053513Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Dec 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL) comparing Zanubrutinib maintenance monotherapy, Ibrutinib maintenance monotherapy and Initial ibrutinib with switch to zanubrutinib (3 arms). Primary endpoint: Progression-free survival. Started Dec 2021; status: recruiting.
02
Drugs
zanubrutinibibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ChiCTR2100053513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053513.